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Abstract: Human cytomegalovirus (CMV) is often transmitted through saliva. The salivary gland
is a site of CMV replication and saliva can be used to diagnose congenital CMV infections. CMV
replication is monitored in whole blood or plasma in renal transplant recipients (RTR) and associates
with clinical disease. However, these assays may not detect replication in the salivary gland and there
is little data linking detection in saliva with systemic infection and clinical sequelae. RTR (n = 82)
were recruited > 2 years after transplantation. An in-house quantitative PCR assay was used to detect
CMV UL54 in saliva samples. CMV DNA was sought in plasma using a commercial assay. Vascular
health was predicted using flow mediated dilatation (FMD) and plasma biomarkers. CMV-reactive
antibodies were quantified by ELISA and circulating CMV-specific T-cells by an interferon-γ ELISpot
assay. Vδ2− γδ T-cells were detected using multicolor flow cytometry reflecting population expansion
after CMV infection. The presence of CMV DNA in saliva and plasma associated with plasma levels
of antibodies reactive with CMV gB and with populations of circulating Vδ2− γδ T -cells (p < 0.01).
T-cells reactive to CMV immediate early (IE)-1 protein were generally lower in patients with CMV
DNA in saliva or plasma, but the level of significance varied (p = 0.02–0.16). Additionally, CMV DNA
in saliva or plasma associated weakly with impaired FMD (p = 0.06–0.09). The data suggest that CMV
detected in saliva reflects systemic infections in adult RTR.
Keywords: cytomegalovirus infection; saliva; renal transplantation
1. Introduction
Human cytomegalovirus (CMV) is a beta-herpesvirus carried by ~83% of the global adult
population [1]. In healthy individuals, most acute infections are asymptomatic but chronic infections
have been linked with diseases of aging, notably cardiovascular disease (CVD) [2]. In individuals with
acquired immunodeficiencies, such as organ transplant recipients, CMV can cause acute end-organ
disease and/or contribute to risk of graft rejection, CVD and secondary bacterial and fungal infections [3].
Symptomatic CMV infections occurs in 20–60% of transplant recipients depending on donor and
recipient CMV status, type of organ transplanted, degree of immunosuppression and use of anti-viral
prophylaxis [4].
The burden of CMV in an individual can be measured directly by the detection of CMV DNA or
indirectly via specific immune responses (antibodies in plasma or CMV-specific T-cells). IgG antibodies
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reactive with CMV assessed in plasma or serum reflect a lifetime history of infection. High titers of
CMV-reactive IgG antibodies have been associated with all-cause mortality, development of CVD
and reduced responses to influenza vaccination in elderly populations [5]. Similarly, high CMV
antibody levels in individuals living with human immunodeficiency virus (HIV) are associated with
cerebrovascular disease and CVD [6]. However, the interpretation of antibodies in this context is
confounded because antibody levels increase as HIV patients achieve an immunological response to
antiretroviral therapy [7]. Once HIV patients are stable on therapy, higher T-cell responses (particularly
CD8+ T-cell responses to immediate early (IE)-1 protein) suggest a high burden of CMV [8]. However,
this response may represent a lifetime of persistent infections that are predominantly latent, as in older
CMV seropositive adults, up to 23% of the entire CD8+ T-cell compartment can be CMV-specific [9].
It may also be possible to assess the CMV burden based on novel populations of natural killer
(NK) and T-cells that have been linked with CMV seropositivity and constitute an “immunological
footprint” [10]. This includes a subset of gamma delta (γδ) T-cells. γδ T-cells constitute < 5% of
circulating T-cells in healthy adults [11]. Most are Vγ9+ and Vδ2+, while Vδ2− (mainly Vδ1+ and Vδ3+)
cells predominate in mucosal epithelia [12]. Populations of Vδ2− γδ T-cells are expanded in renal
transplant recipients (RTR) and healthy adults who are CMV-seropositive [13].
RTR who are seronegative for CMV and receive an organ from a seropositive individual have a
high risk of clinical sequelae [4] and are routinely managed with anti-viral medication prophylaxis to
prevent clinical disease [14]. Following transplantation, CMV DNA is routinely monitored in plasma
or whole blood; whole blood may offer greater sensitivity [15–17]. However congenital CMV is usually
monitored using urine or saliva according to clinical practice guidelines [18]. CMV replicates in acinar
cells of the salivary gland and saliva is a common route of transmission [19]. Saliva is easily collected
as a non-invasive sample, but the value of detecting CMV in the saliva of adults is not well understood.
The present study utilizes clinical and immunological measures of the systemic footprint of CMV
to assess the value of detecting CMV DNA in saliva samples compared with a commercial assay based
on CMV DNA in plasma.
2. Results
2.1. Frequency of CMV DNA Detection in Saliva and Plasma
RTR were screened for the presence of CMV DNA in saliva samples using an in-house qPCR
assay and in plasma using a commercial assay (Abbot Molecular). CMV DNA was detected in 11 (13%)
saliva samples and 16 (21%) plasma samples. Nine individuals had detectable CMV DNA in both
saliva and plasma, so detection of CMV DNA in saliva was more common in RTR who had CMV DNA
in their plasma (p < 0.0001).
2.2. CMV DNA Detected in Saliva is Associated with Immunological Responses to CMV
All comparisons are shown in Supplementary Table S1 and informative comparisons are presented
in Figure 1. The presence of CMV DNA in saliva or plasma from RTR associated with plasma levels
of CMV antibodies detected with gB antigen (Figure 1A, p = 0.009 and Figure 1B, p = 0.006) and
populations of Vδ2− γδ T-cells (Figure 1C, p = 0.01 and Figure 1D, p = 0.005). Presence of CMV DNA
in saliva also associated with increased T-cell responses to the VLE peptide (Figure 1G, p = 0.02) which
is a component of the IE-1 antigen. T-cell responses to IE-1 peptide pool followed a similar pattern
(Figure 1E, p = 0.14). The presence of CMV DNA in plasma associated with increased T-cell responses
to IE-1 peptides (Figure 1F, p = 0.04) and generally higher VLE-specific T-cell responses (Figure 1H,
p = 0.16). T-cell responses to the NLV peptide were higher in individuals carrying CMV DNA in saliva
(Figure 1K, p = 0.03) and followed a similar trend in patients with CMV DNA in plasma (Figure 1L,
p = 0.54). However, one patient with CMV DNA in saliva and high NLV-specific T-cell responses had
no CMV DNA in plasma detected with the Abbot Molecular qPCR assay, so this did not approach
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significance. There were no associations with antibodies targeting CMV lysate or IE-1, T-cell responses
to CMV lysate or pp65 pooled peptides, or inflammatory biomarkers (Supplementary Table S1).
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antigen. Plots (G) and (H) compare T-cell responses to the VLE peptide. Plots (I) and (J) compare 
T-cell responses to the pp65 antigen. Plots (K) and (L) compare T-cell responses to the NLV peptide 
reported as interferon-γ spot forming units per 200,000 cells. Points colored red represent CMV 
seronegative individuals. 
2.3. CMV DNA Displayed Weak Positive Associations with Cardiovascular Risk 
The presence of CMV DNA in saliva or plasma associated weakly with inferior flow mediated 
dilatation (FMD) (Figure 2A, p = 0.087 and Figure 2B, p = 0.062). There were no associations with 
carotid intima media thickness (cIMT) (p > 0.52; Supplementary Table S1) but biomarkers associated 
with CVD showed some consistent trends. The presence of CMV DNA in plasma associated with 
plasma levels of VCAM-1 (Figure 2D, p = 0.03), with a similar trend to levels of ICAM-1 
(Supplementary Table S1). Accordingly, high VCAM-1 correlated weakly with reduced FMD (p = 
0.04, r = –0.24), whilst there was no correlation between ICAM-1 and FMD. The pattern was similar 
when CMV DNA was assessed in saliva, but the trends were not significant (Figure 1C p = 0.27 and 
Figure 1D p = 0.20, respectively). Additionally, levels of p-selectin in plasma were lower in RTR with 
CMV DNA in saliva or plasma (p = 0.01). 
Figure 1. u an cytomegalovirus (CMV) DNA was detected using an in-house qPCR targeting UL54
in saliva or a commercial assay (Abbot Molecular) in plasma. Plots (A) and (B) compare levels of gB
reactive antibodies in plasma. Plots (C) and (D) compare populations of Vδ2− γδ T-cells as a percentage
of CD3+ cells. Plots (E) and (F) compare T-cell responses to the immediate early (IE)-1 antigen. Plots (G)
and (H) compare T-cell responses to the VLE peptide. Plots (I) and (J) compare T-cell responses to the
pp65 antigen. Plots (K) and (L) compare T-cell responses to the NLV peptide reported as interferon-γ
spot forming units per 200,000 cells. Points colored red represent CMV seronegative individuals.
2.3. CMV DNA Displayed Weak Positive Associations with Cardiovascular Risk
The presence of CMV DNA in saliva or plasma associated we kly with inferior flow mediated
dilatation (FMD) (Figure 2A, p = 0.087 and Figure 2B, p = 0.062). There were no associations with
carotid intima media thickness (cIMT) (p > 0.52; Supplementary Table S1) but biomarkers associated
with CVD showed some consistent trends. The presence of CMV DNA in plasma associated with
plasma levels of VCAM-1 (Figure 2D, p = 0.03), with a similar trend to levels of ICAM-1 (Supplementary
Table S1). Accordingly, high VCAM-1 correlated weakly with reduced FMD (p = 0.04, r = −0.24),
whilst there was no correlation between ICAM-1 and FMD. The pattern was similar when CMV DNA
was assessed in saliva, but the trends were not significant (Figure 1C p = 0.27 and Figure 1D p = 0.20,
respectively). Additionally, levels of p-selectin in plasma were lower in RTR with CMV DNA in saliva
or plasma (p = 0.01).
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Figure 2. DNA was detected using an in-house qPCR targeting UL54 in saliva or a commercial
assay (Abbot Molecular) in plasma. Plots (A) and (B) compare flow mediated dilatation (FMD). Plots
(C) and (D) compare levels of VCAM-1 in plasma. Plots (E) and (F) compare levels of ICAM-1 in
plasma. Plots (G) and (H) compare levels of p-selectin in plasma. Points colored red represent CMV
seronegative individuals.
3. Discussion
Our study evaluated the utility of detecting CMV DNA in saliva samples from RTR. Saliva was
pursued as a non-invasive alternative to blood because it may capture bursts of CMV replication in
acinar cells [20]. CMV replication can be missed when assessed in plasma from HIV patients with
CMV disease [21]. We provide evidence that detection of CMV DNA in saliva is reflective of systemic
immune responses to the virus, marked by antibody and T-cell responses. The associations mirror
those seen when CMV DNA was detected in plasma with a clinical assay used to monitor CMV
after transplantation.
The presence of CMV DNA at either site associated with levels of gB antibody, but not with
antibody reactive with CMV lysate or IE-1. There is considerable evidence that gB is a major target for
the immune system [22,23]. Moreover, gB is a vaccine candidate and a recent longitudinal study of this
cohort suggests that antibodies against gB may be protective against deterioration of cardiovascular
health measured by FMD (Affandi et al., submitted for publication). One seronegative individual tested
positive for CMV DNA in saliva but was not assessed by the Abbot assay. The patient did not have
detectable IgM reactive with CMV gB in plasma or saliva (data not shown). However, the transplanted
kidney was from a seropositive donor and it is notable that seroconversion did not occur. Overall,
26 plasma and seven saliva samples were assessed for IgM reactive with CMV gB. Only one sample
had detectable IgM and it was present in both plasma and saliva (data not shown). This suggests that
new infections are rare—a contention supported by assessments of γδ T-cells.
The presence of CMV DNA in saliva or plasma was also associated with similarly elevated
proportions of Vδ2− γδ T-cells. These comprise cells expressing Vδ1, Vδ3 and Vδ5. In our cohort, Vδ2−
γδ T-cells represent around 0.5% of the T-cell population in CMV-seronegative RTR and 5–10% in
seropositive RTR [13]. The likelihood that detection of CMV DNA several years after transplantation is
due to reactivation rather than a primary infection may explain the clear association between increased
populations of Vδ2− γδ T-cells and CMV DNA positivity. Similar findings were noted by Pitard et al.
who linked maximal changes in T-cell populations with reactivation rather than primary infection. They
compared donor negative/recipient positive (D−/R+) renal transplants resulting in a CMV reactivation
event with D+/R− transplants where there was a primary CMV infection [24].
Int. J. Mol. Sci. 2019, 20, 5230 5 of 9
Detection of CMV DNA in plasma associated significantly with T-cell (CD4+ and CD8+) responses
to the IE-1 peptide pool and weakly with CD8+ T-cell responses to the IE-1 peptide, VLE. Detection of
CMV DNA in saliva associated significantly with T-cell responses to VLE and weakly with responses
to the IE-1 peptide pool. In RTR, strong T-cell responses to IE-1 may decrease graft rejection and
improve graft function [25]. IE-1 is the first protein expressed during reactivation, so IE-1-reactive
T-cells may control bursts of replication quickly. CMV DNA in saliva also associated with increased
CD8+ T-cell responses to the pp65 peptide, NLV, but not with T-cell responses to pp65 peptide pools
(Figure 1I–L). Accordingly, Leng et al. associated NLV T-cell responses with the presence of CMV DNA
from peripheral blood mononuclear cells (PBMC) in adults over 70 years of age [26].
In this cohort, levels of CMV antibody were an independent marker of reduced FMD [27] and
CMV DNA in both saliva and plasma aligned weakly with impaired FMD. FMD is an assessment of
endothelial function based on the ability of the artery to respond to shear stress [28]. Associations
between CMV and cardiovascular disease have been validated in a meta-analysis [2]. Here, CMV DNA
in plasma also associated with levels of VCAM-1, and levels of ICAM-1 followed a similar trend.
VCAM-1 and ICAM-1 are cell adhesion molecules that bind to integrins to aid in the transcellular
migration of leukocytes. Both are expressed in atherosclerotic lesions [29,30].
p-selectin is a cell adhesion molecule expressed on platelets and endothelial cells. p-selectin
is implicated in the formation of atherosclerotic lesions in mice [31] and myocardial infarction in
humans [32]. Paradoxically, CMV DNA in plasma or saliva associated with decreased levels of
p-selectin in plasma. Moreover, elevated plasma p-selectin associated with increased FMD in healthy
adults recruited in parallel with the RTR described herein (Affandi et al., submitted for publication).
Studies of cell-bound and soluble p-selectin are required to unravel the pathways invoked.
The current study assessed the systemic effect of detecting CMV DNA in saliva in RTR who were
>2 years post-transplant and clinically stable at the time of recruitment. Futures studies are needed to
address the clinical utility of detecting CMV DNA in saliva in individuals at risk of active disease.
4. Materials and Methods
4.1. Study Cohort
Eighty-two RTR were recruited from renal clinics at Royal Perth Hospital (Western Australia).
Inclusion criteria were clinical stability >2 years after transplant, no CMV disease or reactivation within
6 months of sample collection and no current anti-viral treatment. RTR infected with hepatitis B or
C were excluded. Ethics approval was obtained from Royal Perth Hospital Human Research Ethics
Committee (approval number: EC 2012/155) and endorsed by Curtin University Human Research
Ethics Committee (approval number: HR16/2015). Participants provided written informed consent.
4.2. Detection of CMV DNA in Plasma and Saliva
Saliva (approximately 5 mL) was collected after a water mouth wash by asking the participant to
spit into a 50 mL centrifuge tube. Samples were centrifuged (1000× g, 10 min). DNA was extracted
from the pellet using FavorPrep Blood Genomic DNA Extraction Mini Kits (Favorgen, Ping-Tung,
Taiwan) and stored at −80 ◦C. CMV was detected using an in-house qPCR assay with primers targeting
the UL54 gene (CMV DNA polymerase) [7]. Quantitation was achieved using a standard curve created
using DNA extracted from a lysate of CMV (AD169)-infected HFF which was serially diluted 10-fold.
Samples were considered positive if a steady amplification curve was initiated before 38 cycles (a
cut-off based on the lowest point on the standard curve). Positive results were normalized against
the gene encoding beta-2-microgobulin and values were reported in arbitrary units (range: 44–721).
CMV DNA was also detected in EDTA plasma using the Abbot Molecular assay (Abbot Laboratories,
Chicago, IL, USA) in the Department of Microbiology, Royal Perth Hospital (Western Australia). Five
seronegative plasma samples were not assessed using the Abbot Molecular assay and were excluded
from analyses. The Abbot assay reported samples as either “Not detected”, “< 20 copies/mL” or as
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a viral load. Samples with viral loads or reported as <20 copies/mL were analyzed as CMV DNA
positive. The two assays do not provide viral loads on the same scale; analyses compare samples
grouped as CMV DNA positive or negative.
4.3. Immunological Assessments of CMV Burden
Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll density centrifugation. Plasma
was stored in −80 ◦C and PBMC in liquid nitrogen. Plasma CMV IgG titers were assessed using
in-house ELISAs based on a lysate of fibroblasts infected with CMV AD169, recombinant CMV gB
(Chiron Diagnostics, Medfield, MA, USA) or IE-1 protein (Miltenyi Biotech, Cologne, Germany).
Results are presented as arbitrary units (AU)/mL based on a standard plasma pool [23], allowing
comparisons between people but not between antigens. Plasma levels of vascular biomarkers (p-selectin,
ICAM-1 and VCAM-1) and inflammatory biomarkers (sTNFR1, sCD14 and CRP) were quantified
using commercial ELISA antibody pairs (R&D Systems, Minneapolis, MN, USA).
PBMC were used to assess T-cell responses to CMV lysate and peptide pools derived from pp65
and IE-1 (JPT Peptide Technologies; Berlin, Germany) via ELISpot assay. These antigens and peptide
pools are known to stimulate CD4+ and CD8+ T-cell responses. CD8+ T-cell responses to NLV and
VLE peptides (derived from pp65 and IE-1, respectively) were assessed in samples from individuals
who carried human leukocyte antigen (HLA)-A2. PBMCs were also used to enumerate Vδ2− γδ T-cells
using multicolor flow cytometry, as the population is expanded in CMV-seropositive RTR [13].
4.4. Assessment of Vascular Pathology
Ultrasonography was used to assess carotid intima media thickness (cIMT) and flow mediated
dilatation (FMD) of the brachial artery after 10 min of rest [33]. cIMT is a measurement of the thickness
of the inner layer (intima) of the carotid artery and is a marker of subclinical atherosclerosis. FMD
assesses the ability of the larger conduit artery to respond to shear stress via endothelial-dependent
and -independent mechanisms.
4.5. Statistical Analyses
Mann–Whitney non-parametric statistics and Fisher′s exact tests utilized GraphPad Prism version
8 for Windows (Graphpad Software, La Jolla CA, USA). Comparisons achieving p< 0.05 were considered
significant while comparisons achieving 0.05 < p < 0.1 are noted as a trend.
5. Conclusions
This study addressed the utility of detecting CMV DNA in saliva in RTR compared with assays
using plasma in clinical settings. We show that CMV DNA detected in saliva reflects systemic infection
as assessed by antibody and T-cell responses and note a trend of impaired cardiovascular health
assessed by FMD when CMV DNA was present at either site.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/20/
5230/s1.
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Abbreviations
AU Arbitrary units
cIMT Carotid intimal media thickness
CMV Human cytomegalovirus
CVD Cardiovascular disease
FMD Flow mediated dilatation
PBMC Peripheral blood mononuclear cells
qPCR Quantitative PCR
RTR Renal transplant recipients
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